Research Study Participation

Ongoing Research Studies

The Grunberger Diabetes Institute is currently conducting several clinical research studies aimed at controlling blood glucose more adequately, halting or delaying the onset or progression of complications from diabetes, and delaying or preventing the onset of the disease.

The program offers studies to individuals with type 1 and type 2 diabetes mellitus, between the ages of 18 and 80 years of age. Participation may involve anywhere from 15 weeks to over 6 years, depending on the study.

Research Studies - Blood Sugar Control

1. "Once-A-Week GLP-1 Analog Studies"
   (Study coordinator: Prathima Nagireddy)
   These research studies are for overweight patients with type 2 diabetes who take only one or two oral medications for sugar control and whose A1C result is above 7.0 %. All of these studies involve once a week injection of GLP-1 analogs (similar idea as Byetta or Victoza) which might help with diabetes management and weight loss. All tests, diabetes supplies and oral medications will be provided at no cost to participants.
2. Medication which lowers sugar by increasing its secretion by the kidneys
   (Study coordinator: Delaine Douglas)
   This is a study patients with type 2 diabetes failing one or two pills. The once-a-day pill promotes sugar excretion in the urine and thus should improve diabetes control. 
3. ACCORD/ACCORDION Trial                                                                                                                                                                                     (Study coordinator: Delaine Douglas)                                                                                                                                                                           Type 2 diabetes is a condition that is closely linked to obesity and places people who have the disease at greater risk of cardiovascular disease (CVD). People with type 2 diabetes die of CVD at rates 2 to 4 times higher than those who do not have diabetes. They also experience more nonfatal heart attacks and strokes. Grunberger Diabetes Institute is one of 70 clinics in the United States and Canada taking part in a major study that is testing three approaches to lower the risk of heart disease and stroke in adults with type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). ACCORD was testing the effects of intensive glucose control, treatment to increase HDL ("good")-cholesterol and lower triglycerides, and of intensive blood pressure control on major CVD events. 10,251 participants have enrolled. The trial portion of ACCORD finished on June 30, 2009. Several years of observational follow-up studies will continue for those enrolled. More information about the ACCORD study can be found on the web at www.accordtrial.org.
4. Long-term Cardiovascular Benefit and Safety of GLP-1 analogs 
   a. EXSCEL (once-a-week exenatide) - study coordinator Delaine Douglas

         b. LEADER (liraglutide) - study coordinator Prathima Nagireddy

^ Up to Top

Research Studies - Cardiovascular

1. AIM-HIGH
   (Study coordinator: Delaine Douglas)
   AIM-HIGH is a cholesterol management program funded by the U.S. National Heart, Lung, and Blood Institute (a part of the U.S. National Institutes of Health) with support from Abbott Laboratories . This study compares how two different FDA-approved treatments that affect cholesterol levels may reduce the risk of heart attacks, stroke and other heart-related complications. The two FDA-approved treatments used in AIM-HIGH are:

   * Simvastatin (or Zocor®) taken alone
   * Simvastatin taken with extended-release niacin (Niaspan®)

   The AIM-HIGH cholesterol program enables patients to receive cholesterol medications and access to medical experts at no cost to them or their insurers. Medications, lab tests and office visits related to the study are provided at no cost.

^ Up to Top

Sign Up for a Research Study